ArticleCureus2025
Sudden-Onset Severe Thrombocytopenia Secondary to Trimethoprim-Sulfamethoxazole.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced immune thrombocytopenia (DITP) is a rare but life-threatening condition characterized by a sudden and serious drop in the number of platelets from drug-dependent antibodies against platelet glycoproteins. We report the case of a 57-year-old man who developed severe thrombocytopenia and mucocutaneous bleeding following a short course of trimethoprim-sulfamethoxazole (TMP-SMX) for presumed tick-borne disease. The patient experienced bleeding gums, pinpoint rashes, bruising, and extreme fatigue. The laboratory tests indicated a severely low platelet count of 1 × 1.0 × 10³/µL combined with a high immature platelet fraction (IPF). Workup for both infection and autoimmune disorders would be negative, along with the absence of intracranial hemorrhage demonstrated on imaging. The timeline and clinical picture suggested that TMP-SMX was the most likely culprit. The patient was placed on supportive care, including platelet transfusion and re-start of doxycycline after discontinuation of the drug. His platelet count began to rise, and his symptoms improved; he was discharged without issues. By presenting this instance, we place high importance on early recognition and immediate withdrawal of the offending agent to prevent life-threatening bleeding. Though confirmatory testing of antibodies is available, clinical diagnosis remains the gold standard due to delays in testing and availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.